Severe Asthma clinical trials

Explore recruiting severe asthma clinical trials.

Recruiting severe asthma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Asthma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

AIM4: Next Step – Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma

Poland, Denmark, Germany

Therapeutic use (Phase IV) EU CTIS Study details

A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants with Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL)

France, Italy, Greece, Spain, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

Belgium, Hungary, Spain, Bulgaria, Italy, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

Czechia, Spain, Germany, Austria, Lithuania, Hungary +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)

Portugal, Greece, Germany, Czechia, Slovakia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Severe Asthma trials by city

Severe Asthma in Toronto Severe Asthma in Vancouver Severe Asthma in Montreal Severe Asthma in Calgary Severe Asthma in Edmonton Severe Asthma in Ottawa Severe Asthma in Winnipeg Severe Asthma in Quebec City Severe Asthma in Hamilton Severe Asthma in Kitchener Severe Asthma in London Severe Asthma in Halifax Severe Asthma in New York Severe Asthma in Los Angeles Severe Asthma in Chicago Severe Asthma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease